Today: 21 January 2026
Subscribe
Browse Category

NASDAQ:IBRX News 20 January 2026 - 21 January 2026

ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

ImmunityBio (IBRX) stock slips premarket after FDA maps fresh ANKTIVA resubmission route in bladder cancer

New York, January 21, 2026, 08:47 EST — Premarket ImmunityBio’s stock dropped 5.9% to $6.10 in premarket trading Wednesday. The move followed the company’s announcement of a meeting with the U.S. Food and Drug Administration to discuss a possible resubmission of its bladder-cancer treatment, ANKTIVA. (MarketScreener) This move is significant because the FDA rejected ImmunityBio’s application last year to expand…
21 January 2026
·····
ImmunityBio (IBRX) stock jumps on FDA’s 30-day ANKTIVA resubmission path — what’s next

ImmunityBio (IBRX) stock jumps on FDA’s 30-day ANKTIVA resubmission path — what’s next

New York, January 20, 2026, 20:22 ET — The market has closed. Shares of ImmunityBio, listed on Nasdaq, surged Tuesday following news that U.S. regulators outlined a potential path for the company to pursue an expanded bladder cancer indication for its drug ANKTIVA. The stock closed up 17.7% at $6.48, after trading between $4.94 and $7.97 on heavy volume. (Business…
21 January 2026
·····
ImmunityBio (IBRX) stock jumps after FDA signals ANKTIVA resubmission path in bladder cancer

ImmunityBio (IBRX) stock jumps after FDA signals ANKTIVA resubmission path in bladder cancer

New York, January 20, 2026, 12:42 ET — Regular session ImmunityBio, Inc. shares climbed roughly 24% to $6.82 by midday Tuesday after the company revealed the U.S. Food and Drug Administration provided guidance that could pave the way for a resubmission of its bladder cancer drug ANKTIVA. Earlier, the stock hit $7.97, fluctuating between $4.94 and $7.97 on about 159…
20 January 2026
····

Stock Market Today

  • Boost Electronic Arts (EA) Yield From 0.4% to 3.4% Using Covered Calls
    January 21, 2026, 12:09 PM EST. Shareholders of Electronic Arts Inc (EA) can increase their income by selling February covered calls at the $205 strike. This strategy adds an annualized 3% premium on top of EA's 0.4% dividend yield, creating a 3.4% total return if the stock is not called away. If the stock rises above $205, gains beyond that are capped, but a 0.7% total return including dividends is still possible. EA's trailing twelve-month volatility stands at 32%, informing risk assessment. Options traders show a strong preference for call contracts, with call volume exceeding puts at a 0.43 ratio versus a usual 0.65, indicating bullish sentiment. This covered call tactic offers a way for EA shareholders to enhance returns amid a volatile market environment.
Go toTop